AnticoagEvaluator vs HAS
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
AnticoagEvaluator
This medical app assists healthcare professionals in making informed decisions regarding antithrombotic therapy for patients with non-valvular atrial fibrillation. It calculates patient risk factors, provides guideline-driven therapy recommendations, and helps optimize anticoagulant dosages.
- Calculate renal function and stroke/bleed risk
- Review ACC/AHA/HRS guideline therapy
- Generate individualized antithrombotic risk
- Optimize DOAC dosages
- Based on SPARC Tool
Read full descriptionHide full description
Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator. Use the app to: • Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed • Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention • Generate individualized risk for antithrombotic therapy options based on individual clinical trials. • Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics. This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
HAS
Read full descriptionHide full description
HAS-BLED bleeding risk calculator. Base on the article in Chest. 2010;138(5):1093-1100. doi:10.1378/chest.10-0134. The calculator estimates one year risk of major bleeding when using warfarin in atrial fibrillation. SOG's calculator has been designed with ease of use and clarity in mind. All selections are made on a single page and you can see the risk score and risk assessment change as you switch the options.
Screenshots
Verdict
The clearest difference is price: AnticoagEvaluator at Free against HAS's $0.99. HAS's advantage is update cadence (every 3 weeks vs every 7 months) and iOS requirement (8.0 vs 11.0). On ads, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
AnticoagEvaluator is free to download; HAS costs $0.99 up front. Neither carries in-app purchases, so what you see is what you pay.
AnticoagEvaluator ships an update every 7 months, HAS every 3 weeks. The most recent releases landed on October 12, 2026 and October 6, 2026 respectively.
| Parameter | AnticoagEvaluator | HAS |
|---|---|---|
| Price | Free — better | $0.99 |
| Rating | 2.3 (3 ratings) — better | — |
| Positive reviews | 30.0% of reviews | — |
| Number of ratings | 3 — better | — |
| Update frequency | Every 7 months | Every 3 weeks — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | — |
| Devices | iPhone, iPad, iPod — better | iPhone, iPod |
| Requires iOS | 11.0 | 8.0 — better |
| Further details — not scored | ||
| Size | 25 MB | 9 MB |
| Age rating | 17+ | 17+ |
| Developer | American College of Cardiology | Timo Strid |
In-app purchases
AnticoagEvaluator
No in-app purchases
HAS
No in-app purchases
Questions
Is AnticoagEvaluator free?
Is HAS free?
Do AnticoagEvaluator or HAS have ads?
Which is updated more often, AnticoagEvaluator or HAS?
Other comparisons
